Antifungals in Clinical Use and the Pipeline.
Journal Article (Journal Article;Review)
Over the past 15 years, there has been an increase in the development and utilization of newer antifungal agents. The ideal antifungal, however, in regard to spectrum of activity, pharmacokinetic/pharmacodynamic properties, development of resistance, safety, and drug interaction profile remains elusive. This article reviews pharmacologic aspects of Food and Drug Administration-approved polyenes, flucytosine, azoles, and echinocandins as well as promising pipeline antifungal agents. Unique properties of these newer agents are highlighted. The clinical role of established and investigational antifungal agents as treatment and/or prevention of invasive fungal infections is discussed.
- Johnson, MD
- June 2021
Volume / Issue
- 35 / 2
Start / End Page
- 341 - 371
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)
- United States